氟哌噻吨美利曲辛联合埃索美拉唑、伊托必利治疗NERD疗效观察  

Clinical observation of flupentixol and melitracen tablets combined with esomeprazole,itopride in treatment of refractory non-erosive reflux disease

作　　者：叶伟智[1] 包福元[1] 朱兰惠[1] 

机构地区：[1]广东省湛江中心人民医院消化内科,广东湛江524000

出　　处：《中国当代医药》2010年第22期84-85,共2页China Modern Medicine

摘　　要：目的:探讨氟哌噻吨美利曲辛(黛力新)联合埃索美拉唑及伊托必利治疗顽固性非糜烂性反流病(NERD)的临床价值。方法:对84例确诊为非糜烂性反流病,在使用常规制酸治疗后,症状改善不明显的患者进行随机对照研究,治疗组应用埃索美拉唑、伊托必利、氟哌噻吨美利曲辛口服,对照组应用埃索美拉唑、伊托必利口服,对症状改善的有效率进行统计分析。结果:治疗组及对照组对症状改善均有效,而应用氟哌噻吨美利曲辛联合治疗组的总有效率高于对照组,两组临床疗效比较,差异无统计学意义(P>0.05)。结论:埃索美拉唑、伊托必利治疗顽固性非糜烂性反流病有明显疗效,而联合氟哌噻吨美利曲辛,疗效更为确切,值得在临床上加以推广。Objective： To explore the clinical value of flupentixol and melitracen tablets combined with esomeprazole and itopride in treatment of refractory non-erosive reflux disease（NERD）.Methods： 84 patients of non-erosive reflux disease had no obvious symptomatic improvement in the use of conventional sulfuric acid treatment were observed randomly.The treatment group were given esomeprazole,itopride,flupentixol and melitracen tablets oral and the control group were given esomeprazole,itopride oral.Efficiency of symptom improvement were statistically analyzed.Results： The two groups were valid for symptom improvement,while the effective rate of treatwent group was higher than the control group.The clinical efficacy of the two groups had no significant difference（P〈0.05）.Conclusion： Esomeprazole,itopride are significantly effective in treatment of refractory non-erosive reflux disease,while the effect of joint flupentixol and melitracen tablets group is more precise,is worthy of promoting in clinical practice.

关 键 词：埃索美拉唑 伊托必利 氟哌噻吨美利曲辛 非糜烂性反流病 药物疗效 

分 类 号：R975[医药卫生—药品]